Form 4 Regeneron Pharmaceuticals Inc For: 7 July By Investing.com
This article announces the filing of Form 4 for Regeneron Pharmaceuticals Inc. on July 7th. It indicates that Regeneron Pharmaceuticals (REGN) saw a 4.06% increase. This brief post serves as a notification regarding insider transaction filings.
REGN Maintained by RBC Capital -- Price Target Lowered to $696
RBC Capital has maintained a "Sector Perform" rating for Regeneron Pharmaceuticals (REGN) but lowered its price target to $696 from $707. Despite a strong GF Score of 78/100 and being identified as 26.1% undervalued by GuruFocus, the stock has a low Momentum rank and has seen insider selling. Regeneron is a key player in the biotechnology industry with a market capitalization of approximately $69.95 billion.
Royal Bank Of Canada Has Lowered Expectations for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price
Royal Bank of Canada has decreased its price target for Regeneron Pharmaceuticals (NASDAQ:REGN) from $707 to $696, maintaining a "sector perform" rating. This adjustment follows similar reductions by other analysts, yet the company still holds a "Moderate Buy" consensus rating with an average target price of $790.46. Regeneron recently outperformed quarterly earnings expectations, reporting $9.47 EPS and $3.61 billion in revenue, despite some insider stock sales and the stock trading below its 200-day moving average.
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Swedbank AB
Swedbank AB reduced its stake in Regeneron Pharmaceuticals by 5.4% in the first quarter, selling 12,189 shares. Despite this, analysts maintain a "Moderate Buy" rating with an average target price of $790.92, following strong quarterly results where Regeneron beat EPS and revenue estimates. The stock also saw a 3.1% increase in Tuesday's trading.
Regeneron Pharmaceuticals profile and stock context for US investors
This article provides an overview of Regeneron Pharmaceuticals Inc, a major US biotechnology company listed on Nasdaq. It details the company's business model, diversified pipeline in areas like immunology and oncology, and financial profile. The text also explains the context for US investors, highlighting the stock's long-term growth potential through its pipeline and the importance of understanding the volatility associated with biotech stocks.
RBC Capital Maintains Regeneron Pharmaceuticals(REGN.US) With Hold Rating, Cuts Target Price to $696
RBC Capital has reiterated its Hold rating on Regeneron Pharmaceuticals (REGN.US) but has lowered its price target to $696. This adjustment indicates a continued neutral stance on the company's stock, despite the revision in its valuation forecast.
Benchmark Upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) to Buy
Benchmark has upgraded Regeneron Pharmaceuticals (NASDAQ:REGN) to a "buy" rating, though its target price of $185 is significantly lower than the stock's current trading level of $649.81. Despite Benchmark's low target, other analysts maintain a "Moderate Buy" consensus with an average target price of $790.92. Regeneron recently outperformed quarterly expectations, reporting $9.47 EPS on $3.61 billion in revenue, a 19% year-over-year increase.
RBC Capital Adjusts Regeneron Pharmaceuticals Price Target to $696 From $707, Maintains Sector Perform Rating
RBC Capital has decreased its price target for Regeneron Pharmaceuticals (REGN) to $696 from $707, while maintaining a Sector Perform rating. This adjustment reflects a updated valuation perspective from the analyst firm. The article also notes that HSBC recently adjusted its own price target for Regeneron to $800 from $990.
Regeneron Pharmaceuticals (REGN) Could Be 22% Below Fair Value After Cemdisiran Review Win
Regeneron Pharmaceuticals (REGN) has received attention after its drug cemdisiran was accepted for review in generalized myasthenia gravis, supported by Phase 3 results. Despite recent stock dips, analysts suggest the company is 22% undervalued, with a fair value of $833.31 per share, driven by a strong pipeline and potential for future growth. However, risks like pressure on the EYLEA franchise and high R&D costs tempering optimism.
Regeneron Pharmaceuticals (REGN) Could Be 22% Below Fair Value After Cemdisiran Review Win
Regeneron Pharmaceuticals (REGN) recently had its drug, cemdisiran, accepted for review in the US and Europe, yet its stock has slipped from recent highs, leading to a potential undervaluation of 22% according to Simply Wall St. The company boasts a strong drug portfolio and a promising pipeline in various medical fields, though it also faces risks like pressure on its EYLEA franchise and the high cost of R&D. Investors are encouraged to stress-test this narrative and explore other investment opportunities using the Simply Wall St Screener.
Can Alnylam's Drug Pipeline Fuel Its Long-Term Revenue Growth?
Alnylam Pharmaceuticals currently markets four approved drugs, generating significant revenue growth, and expects further top-line boosts from partnerships like Novartis's Leqvio. The company is advancing a promising pipeline with candidates like cemdisiran, zilebesiran, mivelsiran, and nucresiran, which are in various stages of clinical trials and have the potential to expand its commercial portfolio. Despite stiff competition for its lead drug Amvuttra and an expensive stock valuation, Alnylam is focused on long-term growth through its diversified pipeline.
HSBC Adjusts Price Target on Regeneron Pharmaceuticals to $800 From $990
HSBC has lowered its price target for Regeneron Pharmaceuticals (REGN) from $990 to $800. The firm maintained a "Hold" rating on the stock despite the adjustment, indicating a more cautious outlook on the company's future performance.
Cantor Fitzgerald lowers Regeneron stock price target on Eylea concerns By Investing.com
Cantor Fitzgerald has lowered its price target for Regeneron Pharmaceuticals (NASDAQ:REGN) from $785 to $750, while maintaining an Overweight rating, due to concerns about Eylea HD/SD and Dupixent sales potentially missing consensus estimates, and a lack of clarity regarding Eylea HD's PFS messaging. Despite these concerns, the firm anticipates upside from the Sanofi Collaboration revenue and earnings per share, which, alongside current valuation, may help mitigate some of the market pressure. Regeneron is also actively advancing its pipeline with promising trial results for Lynozyfic, a gene therapy for hearing loss, and expanded collaborations.
Cantor Fitzgerald lowers Regeneron stock price target on Eylea concerns
Cantor Fitzgerald has lowered its price target for Regeneron Pharmaceuticals (NASDAQ:REGN) to $750 from $785, while maintaining an Overweight rating. This decision is driven by expected negative optics around Eylea HD/SD and Dupixent, and a lack of clarity regarding Eylea HD PFS messaging. Despite these concerns, the firm still sees upside potential from the Sanofi collaboration revenue and EPS.
Regeneron (REGN) warns $127M Q2 IPR&D charge will cut EPS by $1
Regeneron Pharmaceuticals, Inc. (REGN) has announced an anticipated pre-tax charge of approximately $127 million in the second quarter of 2026 for acquired in-process research and development (IPR&D). This charge, stemming from collaboration and licensing agreements, is expected to reduce both GAAP and non-GAAP net income per diluted share by about $1.00 for the quarter. The company noted that these are preliminary estimates, and it does not forecast such charges due to their uncertain timing and size.
K.J. Harrison & Partners Inc Trims Holdings in Regeneron Pharmaceuticals, Inc. $REGN
K.J. Harrison & Partners Inc significantly reduced its stake in Regeneron Pharmaceuticals (NASDAQ:REGN) by 91.4% in the first quarter, selling 5,565 shares and retaining 526 shares valued at $406,000. Despite this, other institutional investors either increased their positions or acquired new ones in the biopharmaceutical company. Regeneron recently reported strong quarterly earnings, beating analyst estimates with an EPS of $9.47 and revenue of $3.61 billion, and holds a "Moderate Buy" consensus rating with an average target price of $792.65.
How One Researcher's Personal Study Experience Is Helping Him Better Serve Patients
Kaniel Cassady, Ph.D., an Executive Director in Clinical Sciences at Regeneron, participated in a clinical trial as a patient, profoundly changing his perspective on clinical research. His experience highlighted the crucial role of site staff in patient compliance, the burden of travel, and the importance of patient-reported outcomes in optimizing trial design. Cassady now applies these insights at Regeneron to create more patient-centric clinical trials, advocating for better geographical accessibility and adaptive dosing.
Zanzalintinib Trial Outcomes And Index Exit Might Change The Case For Investing In Exelixis (EXEL)
Exelixis (EXEL) recently faced removal from Russell 1000 defensive indexes and reported mixed zanzalintinib trial results, showing a statistically significant overall survival benefit in the full population but a non-significant trend in a key subgroup. These developments, coupled with an analyst downgrade due to pipeline uncertainty, intensify focus on the FDA's December 2026 decision for zanzalintinib as Exelixis seeks to diversify beyond CABOMETYX. Investors now need to critically evaluate the company's ability to build a second growth pillar and manage pipeline risks.
ARGX - Argen X SE ADR Options
This article provides a comprehensive overview of Argen X SE ADR (ARGX) stock, including its last closing price, financial performance metrics, and various stock indicators. It details market capitalization, income, sales, P/E ratios, EPS, insider and institutional ownership, profitability, and stock performance over different periods. The data also includes analyst recommendations and target prices.
VRTX - Vertex Pharmaceuticals Inc Options
This article provides a detailed financial overview of Vertex Pharmaceuticals Inc (VRTX), including its stock performance, market capitalization, income, sales, and various financial ratios. It also highlights institutional and insider ownership, profitability margins, and analyst recommendations, offering a comprehensive snapshot of the company's financial health and market position.
Is Vertex Pharmaceuticals (VRTX) Undervalued After CASGEVY Won Expanded FDA Approval?
Vertex Pharmaceuticals (VRTX) is gaining attention after the FDA expanded the use of its gene-editing therapy, CASGEVY, for younger patients with sickle cell disease or beta thalassemia. Despite recent share price gains, Simply Wall St's narrative suggests VRTX is still undervalued, with a fair value estimate of $547.72 against a current trading price of $528.04. The analysis highlights projected revenue and profit margin growth, though it cautions that future success depends on pipeline execution and pricing stability.
Should Cemdisiran’s Priority Reviews and First-in-Class siRNA Status Require Action From Regeneron (REGN) Investors?
Regeneron Pharmaceuticals (REGN) recently had its regulatory applications for cemdisiran accepted by the FDA and EMA, positioning it as a potential first-in-class siRNA therapy for generalized myasthenia gravis. While this offers a differentiated autoimmune asset and is a positive development for its pipeline, the company's near-term investor sentiment still heavily relies on the performance of EYLEA and Dupixent. Investors should consider cemdisiran's potential alongside the existing risks of concentrated revenue dependence on Regeneron's established blockbusters.
Should Cemdisiran’s Priority Reviews and First-in-Class siRNA Status Require Action From Regeneron (REGN) Investors?
Regeneron Pharmaceuticals has secured Priority Review for cemdisiran, a potential first-in-class siRNA therapy for generalized myasthenia gravis. This development adds a differentiated autoimmune asset to Regeneron's pipeline and could benefit from the FDA's PreCheck Pilot Program for faster manufacturing site qualification. However, the company still faces risks associated with its concentrated dependence on EYLEA and Dupixent.
Regeneron (REGN) Stock Looks Undervalued Even After A 20% Gain
Regeneron Pharmaceuticals (REGN) stock has seen a 20.2% gain over the past year, yet remains undervalued according to Simply Wall St's analysis across six key areas. The company trades at a P/E ratio of 15.0x, significantly below the biotech industry average and its fair multiple of 25.0x, suggesting its pipeline and long-term earnings power are still underestimated despite recent positive developments like cemdisiran and weight loss programs. The article presents bull and bear cases, highlighting the potential from its advancing pipeline against risks from biosimilar competition to EYLEA.
GMAB - Genmab ADR Earnings
This Finviz article provides a detailed financial overview of Genmab ADR (GMAB), including its last closing price, key financial metrics like market cap, income, sales, P/E ratio, and EPS. It also lists performance indicators, insider ownership, institutional ownership, and analyst recommendations. The data highlights recent stock performance and valuation figures for the biotechnology company.
Simplify Asset Management Inc. Has $8.42 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN
Simplify Asset Management Inc. significantly reduced its stake in Regeneron Pharmaceuticals Inc. by 65% in the first quarter of 2026, ending with 10,900 shares valued at $8.42 million. Despite this reduction, Regeneron reported strong quarterly results, beating EPS and revenue estimates, and analysts maintain a "Moderate Buy" rating with an average price target of $792.65. Other institutional investors have shown mixed activity, while a director sold shares in May.
Fjarde AP Fonden Fourth Swedish National Pension Fund Acquires 11,050 Shares of Regeneron Pharmaceuticals, Inc. $REGN
Fjarde AP Fonden Fourth Swedish National Pension Fund increased its stake in Regeneron Pharmaceuticals (NASDAQ:REGN) by 56.2% in the first quarter, purchasing an additional 11,050 shares. This brings their total holdings to 30,702 shares, valued at $23.72 million. Other institutional investors also significantly increased their positions in REGN, and Wall Street analysts have a "Moderate Buy" consensus rating for the company with an average target price of $792.65.
If You Invested $1,000 in Cytomx Therapeutics Inc (CTMX)
This article analyzes the historical performance of a $1,000 investment in Cytomx Therapeutics Inc (CTMX) over different periods, including 1, 5, and 10 years, and since October 2015. It also provides a detailed company profile, outlining CytomX's focus on conditionally activated biologics for oncology, its proprietary PROBODY® platform, clinical pipeline, and collaborations. The data shows significant volatility and overall negative returns over longer periods, contrasting with a strong gain in the last year.
Regeneron (REGN) Stock Looks Cheap On Earnings While Its 20% Gain Raises Questions
Regeneron Pharmaceuticals (REGN) has seen a 20.2% return over the past year and screens as undervalued across multiple metrics, including a P/E ratio of 15.0x, which is below the biotech industry average and its tailored fair P/E of 24.8x. While regulatory momentum for new treatments offers growth potential, market caution persists due to reliance on EYLEA and the need for successful diversification efforts, creating a debate between bull and bear cases for its valuation. The article suggests that despite appearing cheap on earnings, the key question for investors is whether current market concerns are justified or overly conservative.
Regeneron (REGN) Stock Looks Cheap On Earnings While Its 20% Gain Raises Questions
Regeneron Pharmaceuticals (REGN) stock has seen a 20.2% gain over the past year and screens as undervalued across several valuation metrics, including a P/E ratio of 15.0x, which is below industry averages. Despite this, the market appears to be valuing its earnings cautiously, possibly due to concerns about its reliance on EYLEA and upcoming biosimilar competition. The article suggests investors consider whether the market's discount is justified or an overly conservative view that could close with pipeline progress and diversification.
MDGL - Madrigal Pharmaceuticals Inc Latest SEC Filings
This article provides a detailed financial snapshot of Madrigal Pharmaceuticals Inc. (MDGL), including its latest stock performance, key financial metrics, insider and institutional ownership data, and various valuation ratios. It covers aspects like market capitalization, sales, earnings per share, and stock performance over different periods.
Fideuram Intesa Sanpaolo Private Banking S.P.A. Trims Holdings in Regeneron Pharmaceuticals, Inc. $REGN
Fideuram Intesa Sanpaolo Private Banking S.P.A. reduced its stake in Regeneron Pharmaceuticals (NASDAQ:REGN) by 35.0% in the first quarter, selling 8,072 shares. The fund's remaining 14,975 shares were valued at $11.57 million. Despite this reduction, other institutional investors have increased their holdings, and the company has received a "Moderate Buy" consensus rating from analysts with an average price target of $792.65.
Amgen, Sanofi Team Up To Urge En Banc Antibody IP Review
Rival pharmaceutical companies Amgen and Sanofi have jointly requested a full Federal Circuit review of a decision that revived migraine drug antibody patents. This comes despite their previous clash at the U.S. Supreme Court over antibody patents. The move highlights a shared interest in intellectual property matters within the pharmaceutical industry.
REGN - Regeneron Pharmaceuticals Inc Latest SEC Filings
This article provides a detailed financial overview of Regeneron Pharmaceuticals Inc (REGN), including its latest stock performance, key financial metrics, and company statistics. It covers various aspects like market capitalization, income, sales, dividend information, analyst recommendations, and performance across different timeframes.
Form 144 Regeneron Pharmaceuticals For: 2 July By Investing.com
This article announces a Form 144 filing for Regeneron Pharmaceuticals (REGN) on July 2nd. It's a very brief post and doesn't provide further details about the filing, focusing instead on market data and other news. The article also includes various market indices, commodity prices, and stock performances.
Regeneron (REGN) files Form 144 to resell 400 shares via J.P. Morgan
Regeneron Pharmaceuticals (REGN) has filed a Form 144 notice indicating a proposed resale of 400 shares of common stock through J.P. Morgan Securities LLC. The filing also documents a prior sale of 100 shares on May 1, 2026, for $70,523.79. This is considered a routine affiliate resale notice for a small number of shares, indicating a neutral impact and sentiment.
LEGN - Legend Biotech Corp ADR Options
This page provides a detailed financial overview of Legend Biotech Corp (LEGN), including its stock performance, key financial metrics, insider and institutional ownership, and analyst recommendations. As of July 2nd, the stock closed at $29.91, showing a slight increase. The data presented covers market capitalization, earnings per share, sales growth, profitability ratios, and options-related information, offering a comprehensive snapshot for potential investors.
NTLA Stock Surges 35% Overnight: Retail Mood Peaks Ahead Of First-Ever Phase 3 Readout For Gene-Editing Therapy
Intellia Therapeutics (NTLA) stock surged 35% overnight as retail investors anticipate the results of its Phase 3 Haelo trial for Lonvo-z, a gene-editing treatment for hereditary angioedema. This trial is significant as it marks the first late-stage test of an in-vivo CRISPR gene-editing treatment. The company has also seen recent positive regulatory developments with the FDA lifting clinical holds on two other Phase 3 trials for Nex-z, a treatment for transthyretin amyloidosis.
Wall Street Thinks This High-Flying Biotech Stock Can Soar Another 57%
Intellia Therapeutics (NASDAQ: NTLA) has seen its stock climb significantly this year due to strong clinical progress, particularly with its gene-editing candidate lonvo-z. Wall Street analysts predict the stock could rise another 57% based on its average price target, driven by lonvo-z's successful phase 3 trial and another promising late-stage asset, nex-z. However, the company faces substantial risks, including the commercial viability of its expensive gene-editing treatments and potential regulatory setbacks, making it a volatile investment suitable for those comfortable with high risk.
VRTX - Vertex Pharmaceuticals Inc Dividends
This article provides a detailed financial overview of Vertex Pharmaceuticals Inc (VRTX), including its latest stock performance, market capitalization, income, sales, and various financial ratios. It also lists key statistics such as EPS, sales growth, insider and institutional ownership, and profitability margins. The data indicates strong financial health and growth for the company, despite not paying dividends.
Evommune’s EVO756 Trial Completion Signals Key Milestone in Chronic Urticaria Market
Evommune, Inc. announced the completion of its Phase 2b trial for EVO756, an oral drug designed to treat moderate to severe chronic spontaneous urticaria. This milestone is crucial for investors as positive results could pave the way for a larger Phase 3 program and potential partnerships, impacting future revenue in the chronic allergy market. The company's stock (EVMN) will likely be influenced by the upcoming release of detailed efficacy and safety data.
Harrow Announces Commercial Launch of BYOOVIZ® in the United States
Harrow, Inc. has commercially launched BYOOVIZ® (ranibizumab-nuna), an FDA-approved biosimilar referencing LUCENTIS, in the U.S. This launch expands Harrow's retina portfolio for treating conditions like Neovascular Age-Related Macular Degeneration (AMD). The company obtained exclusive U.S. commercialization rights through a partnership with Samsung Bioepis, further strengthening its presence in the growing retinal biologics market.
Eli Lilly and Regeneron among 7 companies picked for FDA PreCheck pilot program
The FDA has selected seven companies, including Eli Lilly and Regeneron, to participate in its new PreCheck pilot program, which provides early technical guidance for new U.S. pharmaceutical manufacturing facilities. This initiative was prompted by a 2025 presidential order to promote domestic drug production. The selected companies each have one specific site entering the program, with facilities spanning Indiana, New York, North Carolina, and New Jersey, aiming to boost the domestic manufacturing of various pharmaceutical products, including APIs, sterile injectables, and cell-based gene therapies.
How Investors May Respond To Alnylam Pharmaceuticals (ALNY) Expanding Its Enterprise-Wide AI Analytics Partnership
Alnylam Pharmaceuticals has expanded its partnership with Komodo Health to integrate its Marmot AI analytics platform across its enterprise functions. This move, building on previous commercial use, aims to streamline decision-making and enhance insights, though it's seen more as an execution tool than a direct growth driver. While it could improve efficiency, it does not fundamentally alter the core risks associated with Alnylam's high valuation, clinical outcomes, and market competition.
Is Telix (ASX:TLX) Using Vertical Integration To Quietly Redefine Its Radiopharmaceutical Moat?
Telix Pharmaceuticals is leveraging vertical integration and strategic deal-making in manufacturing and distribution to strengthen its position in the radiopharmaceutical market for precision oncology. While the company projects significant revenue and earnings growth by 2029, investors should be aware of potential profitability pressures from rising R&D and infrastructure spending, as well as ongoing risks like Illuccix pricing and an SEC subpoena. The Regeneron collaboration highlights Telix's strategy to build a broader oncology platform despite these challenges.
A first FDA-approved eye biosimilar returns to U.S. sales
Samsung Bioepis has relaunched BYOOVIZ (ranibizumab-nuna) in the US in partnership with Harrow, making the FDA-approved ophthalmology biosimilar referencing LUCENTIS available again. BYOOVIZ was the first ophthalmology biosimilar approved by the FDA in 2021 and received interchangeability designation in 2023. This collaboration aims to improve patient access to critical retinal disease treatments and address the financial burden associated with current anti-VEGF therapies for conditions like Wet Age-Related Macular Degeneration.
Harrow Announces Commercial Launch of BYOOVIZ® in the United States
Harrow has commercially launched BYOOVIZ® (ranibizumab-nuna) in the United States, an FDA-approved interchangeable biosimilar to LUCENTIS, expanding its retina portfolio. This launch follows an exclusive agreement with Samsung Bioepis and aims to provide retina specialists with a clinically proven anti-VEGF therapy for conditions like Wet Age-Related Macular Degeneration. BYOOVIZ joins other Harrow products like IHEEZO and TRIESENCE, strengthening the company's position in the rapidly growing retinal biologics market.
USS Investment Management Ltd Acquires 3,681 Shares of Amgen Inc. $AMGN
USS Investment Management Ltd increased its stake in Amgen Inc. by 4% in Q1, raising its total holdings to 95,031 shares valued at approximately $33.4 million. Amgen reported strong first-quarter earnings, beating analyst expectations with $5.15 EPS and $8.62 billion in revenue. Despite positive financial results, the stock holds a consensus "Hold" rating from analysts with an average price target of $354.42, influenced by some regulatory and competitive pressures on its key drugs.
Lansforsakringar Fondforvaltning AB publ Trims Stock Position in Regeneron Pharmaceuticals, Inc. $REGN
Lansforsakringar Fondforvaltning AB publ reduced its stake in Regeneron Pharmaceuticals (NASDAQ:REGN) by 13.1% in the first quarter, now holding 33,101 shares valued at $25.6 million. Despite this trimming by one institutional investor, the company reported strong financial results, surpassing EPS and revenue estimates, with year-over-year revenue growth of 19%. Analysts generally maintain a "Moderate Buy" rating for REGN, with an average target price of $792.65, though some have recently adjusted their targets.
Element Squared LLC Purchases New Stake in Regeneron Pharmaceuticals, Inc. $REGN
Element Squared LLC initiated a new position in Regeneron Pharmaceuticals (NASDAQ: REGN) during the first quarter, acquiring 2,936 shares valued at approximately $2.27 million. This move highlights continued institutional interest in REGN, with 83.31% of the stock owned by institutions. Regeneron recently reported strong Q1 results, surpassing earnings and revenue expectations, and analysts maintain a "Moderate Buy" rating with an average price target of $792.65.
